Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for MRD Eradication in T-ALL
NCT07021677Phase 2Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Tata Memorial Centre. Started Aug 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT07021677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021677.